Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation

Norberto Perico, Piero Ruggenewnti, Flavio Gaspari, Lidia Mosconi, Ariela Benigni, Carmen S. Amuchastegui, Fabio Gasparini, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


A variety of side effects are associated with the use of cyclosporine, the most relevant of which remains the renal toxicity. We did parallel studies on cyclosporine pharmacokinetics and renal function in patients who had a recent kidney transplant and were given cyclosporine as a part of their immunosuppressive therapy. Seven consecutive renal transplant patients were studied at the end of a month of treatment while on different oral cyclosporine doses (5, 3.5, 2.5, or 1.5 mg/kg, twice a day, respectively). Cyclosporine pharmacokinetics profiles and renal function parameters (GFR and renal plasma flow [RPF], as inulin and p-amino hippurate clearances, respectively) were determined before and over a 12-hr period after each single dose of cyclosporine. Plasma levels and urinary excretion rate of endo-thelin were also studied before and after the highest cyclosporine dose (5 mg/kg). Mean trough levels, area under the curve values, and maximum concentration of blood cyclosporine were comparable after 5 and 3.5 mg/kg cyclosporine and decreased in a dose-dependent manner after the lower doses (2.5 and 1.5 mg/kg). In the same patients GFR declined on average 63%, 53%, 35%, and 18%, 2-4 hr after maximum cyclosporine concentration was reached. As blood levels of cyclosporine returned to trough, GFR progressively increased to baseline. Similar results were found for RPF; 5 mg/kg cyclosporine did not modify endothelin plasma levels. By contrast, urinary excretion of the peptide increased.

Original languageEnglish
Pages (from-to)56-60
Number of pages5
Issue number1
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Fingerprint Dive into the research topics of 'Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation'. Together they form a unique fingerprint.

Cite this